Read about TYSABRI® (natalizumab), a prescription infusion medication for adults, including dosing info, support, & more. See full safety & Boxed Warning.
Learn about TYSABRI®. Find HCP resources here, including insights from peers, infusion site locator, and more. See full ISI & Boxed Warning.
The Power of Me Time Treating with TYSABRI helps give Nicole peace of mind because her care team consistently checks in to see how she’s feeling. First Infusion, First Impressions Despite her nerves before her first infusion, Rosario has found that TYSABRI meets her treatment goals. Feeling ...
infusion-related reactions Interactions Drug-Drug interaction↑ risk of infection with immunosupressants (avoid concurrent use). Route/DosageNOTE: Because of the risk of PML, natalizumab is available only under a special restricted distribution program, the TOUCH Prescribing Program. Prescribers, pharmac...
Useaseptictechnique when preparing TYSABRI solution for intravenous infusion. Each vial is intended for single use only. Discard any unused portion. TYSABRI is a colorless, clear to slightly opalescent solution. Inspect the TYSABRI vial for particulate material and discoloration prior to dilution and ...
deathorseveredisability(5.1)Solution[300mgper15mLvial]fordilutionpriortoinfusion(3) •RiskfactorsforthedevelopmentofPMLludedurationoftherapy,prior useofimmunosuppressants,andpresenceofanti-JCVantibodies.TheseCONTRAINDICATIONS factorsshouldbeconsideredinthecontextofexpectedbenefitwhen•PatientswhohaveorhavehadPML(...
Patients taking Tysabri are to be evaluated at three and six months after the first infusion and every six months after that, and their status will be reported regularly to Biogen Idec and Elan. In addition to its activity in MS, Tysabri is being studied for Crohn's disease. Last month ...
Of 123 with patient preference data, 108 (87.8%) preferred the SC route of administration for natalizumab over the IV route; 102 (82.9%) specified "requires less time in the clinic" as the reason for the SC preference.#In NOVA (part 2), most participants on Q6W dosing of natalizumab ...
–99.9% of patients enrolled at time of infusion ♦ Prescribed as monotherapy, according to label –96.8% patients with no concurrent immunomodulatory or immunosuppressant therapies ♦ Drug being shipped to registered infusion centers –99.9% of 10,126 drug shipments shipped to registered infusion...
On the other hand, targeting B cell cytokines with the fusion protein atacicept increased MS activity, highlighting the complex and not fully understood role of B cells and humoral immunity in MS. Finally, all other approved therapies for MS, some of which have been designed to target T cells...